
TSE:TSU
This summary was created by AI, based on 6 opinions in the last 12 months.
Trisura Group (TSU-T) operates in the specialty insurance sector, showing signs of improving business fundamentals despite industry-wide volatility and a softening cycle. The company commands approximately 30% market share in Canada while actively expanding into the U.S. market, particularly in surety and property insurance. Analysts praise its strong management team and high return on equity (ROE), noting continued growth in book value per share, although the stock has faced pressure from past asset impairments and current market conditions. TSU is considered an attractive acquisition target due to its solid cash position and sound valuation metrics, yet it lacks a dividend. While it has not performed strongly in the short term, there are optimistic projections for its future performance, mainly driven by aggressive expansion and overall improvements in the insurance business climate.
Specialty insurance company with large US book. Volatile stock, but will continue to hold shares. Well run company. High growth company. Insurance lines can product write downs, but management teams learning from mistakes. Expecting growth multiple to grow. Expecting all time stock highs going forward.
EPS of $0.31 missed expectations of $0.4229 and revenues of $769.94M beat estimates of $758.69M. Insurance revenue grew by 32.7% in the quarter, reflecting sustained momentum across North America. Its operating net income was up 50.2%, driven by profitable growth in Canada and core operations in the US. Its net income was impacted by the run-off of a US program and unrealized losses in the investment portfolio, partially offset by one-time benefits in the primary lines business. Its net investment income grew substantially, due to higher risk-adjusted yields and an increased size of the investment portfolio. Its operating ROE of 20.2% exceeded its target, demonstrating the strength of its core operations. Its EPS estimates jump from FY2023 to FY2024 on a GAAP basis, however, non-GAAP, this EPS estimate goes from $2.40 to $2.64. Its balance sheet expanded, it has been issuing less shares than in previous quarters, and shares increased following results, indicating that investors are largely pleased with the results.
Its write-downs are still looming, but its core operations have shown strength and we think it begins to demonstrate its ability to execute and grow in future quarters.
Unlock Premium - Try 5i Free
Has followed business for a long term. Small cap insurance provider that has lots of room for growth. Massive growth the past few years. Taking lessons learned in Canada into the US market. Current share price a great place to buy. Problems from the past year being fixed very quickly. Higher interest rates not presenting problem for the company with cash flow.
Really likes insurance names. Financials have been under pressure, especially in the US. But US insurance names are doing really well. It's turning up, improving. Higher for longer should be a tailwind. Important support level around $30, so limit risk to recent lows. $36 and $42 are next major resistance levels.
EPS of 65c matched estimates; Revenue of $772M was nicely ahead of estimates. Operating ROE was 19.6% vs 19% expected. Sales rose 16%. Net investment income rose 42%. Book value increased 26.3% to $14.56. Operating ratio was 87.5%. Scotia raised its priced target from $62 to $63. We would consider the results good.
Unlock Premium - Try 5i Free